<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/24/zacks-brokerages-expect-anavex-life-sciences-corp-nasdaqavxl-will-post-earnings-of-0-15-per-share.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-24T13:30:04+00:00"/>
    <meta property="og:title" content="Zacks: Brokerages Expect Anavex Life Sciences Corp (NASDAQ:AVXL) Will Post Earnings of -$0.15 Per Share"/>
    <meta property="og:description" content="Analysts expect Anavex Life Sciences Corp (NASDAQ:AVXL) to announce earnings of ($0.15) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Anavex Life Sciences’ earnings. Anavex Life Sciences reported earnings per share of ($0.13) in the same quarter last year, which suggests a negative year-over-year growth rate of […]"/>
  </head>
  <body>
    <article>
      <h1>Zacks: Brokerages Expect Anavex Life Sciences Corp (NASDAQ:AVXL) Will Post Earnings of -$0.15 Per Share</h1>
      <address><time datetime="2019-11-24T13:30:04+00:00">24 Nov 2019, 13:30</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/anavex-life-sciences-corp-logo.jpg"/>
      </figure>
      <p>Analysts expect Anavex Life Sciences Corp (NASDAQ:AVXL) to announce earnings of ($0.15) per share for the current fiscal quarter, according to <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks</a>. Zero analysts have provided estimates for Anavex Life Sciences’ earnings. Anavex Life Sciences reported earnings per share of ($0.13) in the same quarter last year, which suggests a negative year-over-year growth rate of 15.4%. The firm is scheduled to report its next quarterly earnings results on Wednesday, December 11th.</p>
      <p>On average, analysts expect that Anavex Life Sciences will report full year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.63) to ($0.62). For the next financial year, analysts expect that the firm will report earnings of ($0.63) per share, with EPS estimates ranging from ($0.64) to ($0.62). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Anavex Life Sciences.</p>
      <p>Several brokerages have commented on AVXL. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> downgraded Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=AVXL">ValuEngine</a> downgraded Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $9.20.</p>
      <p>A number of institutional investors have recently made changes to their positions in the business. AllSquare Wealth Management LLC grew its position in shares of Anavex Life Sciences by 11.3% during the 3rd quarter. AllSquare Wealth Management LLC now owns 40,424 shares of the biotechnology company’s stock worth $128,000 after buying an additional 4,120 shares in the last quarter. Hikari Power Ltd raised its stake in Anavex Life Sciences by 168.9% in the third quarter. Hikari Power Ltd now owns 468,110 shares of the biotechnology company’s stock valued at $1,479,000 after buying an additional 294,030 shares during the last quarter. Commonwealth Equity Services LLC raised its stake in Anavex Life Sciences by 28.0% in the third quarter. Commonwealth Equity Services LLC now owns 28,185 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 6,157 shares during the last quarter. FormulaFolio Investments LLC purchased a new stake in Anavex Life Sciences in the third quarter valued at about $44,000. Finally, Kessler Investment Group LLC raised its stake in Anavex Life Sciences by 418.0% in the third quarter. Kessler Investment Group LLC now owns 20,721 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 16,721 shares during the last quarter. 23.43% of the stock is currently owned by institutional investors.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/AVXL/earnings/">NASDAQ AVXL</a> traded down $0.09 during trading hours on Friday, reaching $2.31. The company’s stock had a trading volume of 348,200 shares, compared to its average volume of 333,082. The firm’s 50-day moving average price is $2.71 and its 200-day moving average price is $2.93. The company has a market capitalization of $126.36 million, a price-to-earnings ratio of -5.92 and a beta of 2.24. Anavex Life Sciences has a 1 year low of $1.25 and a 1 year high of $4.09.</p>
      <p>
        <b>About Anavex Life Sciences</b>
      </p>
      <p>Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.</p>
      <p>See Also: <a href="https://www.marketbeat.com/financial-terms/understanding-market-liquidity/">Understanding Market Liquidity</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=AVXL">Get a free copy of the Zacks research report on Anavex Life Sciences (AVXL)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=AVXL"/>
      </figure>
    </article>
  </body>
</html>